A pair of FDA-instigated lawsuits filed in Florida and California that seek to stop stem cell clinic operators from marketing unapproved treatments may make a bigger splash than it first seemed.
The agency escalated its clampdown on medical clinics that it says offer unapproved and potentially unsafe stem cell treatments by asking two courts May 9 to allow it to rein them in permanently. But notably, one of the named defendants—Cell Surgical Network Corp.—is actually a network of such clinics.
“By Cell Surgical Network’s account, that’s about 100 clinics. That’s important,” Leigh Turner, associate professor with the University of Minnesota’s ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
